One of the largest randomized trials ever has concluded that ovarian cancer screening may reduce ovarian cancer mortality by an estimated 20 percent after follow up of up to 14 years, but researchers say longer follow-up is needed to determine the ultimate mortality reduction and if screening the general population is cost effective.
The United Kingdom Collaborative Trial of Ovarian Cancer Screening enrolled 202,638 women, aged 50-74 years, between 2001 and 2005 through 13 trial centers in England, Northern Ireland and Wales. The study results were published in The Lancet.
The study tested the hypothesis that screening for ovarian cancer in the general population can reduce disease mortality without significant harm, in line with screening programs for other cancers.
Article from http://www.cancerletter.com/articles/20160201_3